Personalis

PSNL

Börsenwert 1,67 Mrd. $

BALA CYNWYD, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

Personalis (PSNL) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.23 per share a year ago.

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments. Second Quarter and Recent Strategic and Operational Highlights Secured Medicare Coverage for IO Monitoring: Received Medicare coverage approval for NeXT Personal for immunotherapy monitoring for patients with late-stage solid tumors. Se.

MONSEY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- The Monsey law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Personalis, Inc. (Nasdaq: PSNL) (“Personalis”) to Tempus AI, Inc. (“Tempus”) for $16.25 per share.

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner. For a free consultation, please visit https://julieholleman.com/personalis-inc/.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

BALA CYNWYD, Pa., July 27, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Personalis, Inc. (NasdaqGM: PSNL) to Tempus AI, Inc. (NasdaqGS: TEM). Under the terms of the proposed transaction, shareholders of Personalis will receive $16.25 per common share. The consideration is reported to be structured as a 100% stock transaction, with Tempus having the option to elect paymen.